Please ensure Javascript is enabled for purposes of website accessibility

Cannabis Stocks MedMen Enterprises and PharmaCann Scrap $682 Million Merger

By Joe Tenebruso - Updated Oct 14, 2019 at 3:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Changing industry dynamics are forcing these marijuana companies to scuttle a once-promising combination.

MedMen Enterprises (MMNFF 2.48%) and PharmaCann have called off their blockbuster merger. 

The high-end cannabis retailer had originally announced its plans to acquire multistate dispensary company PharmaCann back in October 2018. The deal was intended to double the number of states in which MedMen was licensed to produce and sell cannabis. The combined company was projected to hold licenses for more than a dozen production facilities and 66 retail stores. 

"This is a transformative acquisition that will create the largest U.S. cannabis company in the world's largest cannabis market," MedMen CEO Adam Bierman said at the time. "The transaction adds tremendous scale to our vertically integrated business model by expanding our U.S. retail footprint across important growth markets while strengthening our cultivation and production capabilities." 

A person in a business suit raising his hand out in front of his body with his fingers outstretched

MedMen Enterprises and PharmaCann put a sop to their merger proceedings. Image source: Getty Images.

Now, however, the two companies are backing away from their deal.

"The cannabis sector has evolved tremendously since we first announced the PharmaCann transaction and based on the current macro-environment and future opportunities that exist for our business, we believe it is now in the best interest of our shareholders to deepen, rather than widen, our company's reach," Bierman said in a press release. 

As part of the merger termination agreement, PharmaCann will transfer some cannabis licenses and facilities in Illinois and Virginia to MedMen, pending regulatory approval. In return, MedMen will forgive approximately $21 million of PharmaCann's debt. 

"Looking at the PharmaCann portfolio today, Illinois has emerged as the most attractive opportunity for our longer-term strategic growth plan," Bierman said. "The addition of those assets, without dilution, is a win for MedMen and our shareholders." 

Judging by the performance of MedMen's stock since the announcement on Oct. 8, investors appear to disagree. Shares are down nearly 20% since news of the deal's cancellation broke. 

MedMen's announcement that it had terminated chief financial officer Michael Kramer, which the company made in conjunction with its merger update, no doubt contributed to the decline. Kramer will be replaced by Zeeshan Hyder, who previously served as the company's chief corporate development officer. 

Despite the turnover in its executive ranks and the operational turbulence it may face due to the merger's cancelation, MedMen says that it remains on track to break even on an earnings before interest, taxes, depreciation, and amortization (EBITDA) basis by the end of 2020.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MedMen Enterprises Stock Quote
MedMen Enterprises
$0.06 (2.48%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.